We have several accruing #ClinicalTrials for patients with #SmallCell #BladderCancer 1. #Lurbi +/- #Avelumab LASER clinicaltrials.gov/study/NCT06228… 2. #SG +/- #Atezo SMART clinicaltrials.gov/study/NCT06161… 3. #CaboNivoIpi ICONIC clinicaltrials.gov/study/NCT03866… [email protected] / ☎️240-760-6006

🩸Iron Deficiency for the Practicing Oncologist JCO Oncology Practice ✅A very useful excellent review 👉ascopubs.org/doi/pdf/10.120… ASCO #cancer #oncology #MedX OncoAlert Top Biomedical Science Top Science

Congrats to all the new heme/onc fellows joining the best specialty this week!! This week’s episode focuses on how to prepare for the start of heme/onc fellowship - differences from residency, how to succeed, research & study tips, resources… podcasts.apple.com/us/podcast/two…

🔬 Who Should Get Screened for Pancreatic Cancer? Insights from #ESMOGI25 🔎 📌 High-Risk Germline Mutations 🧬 STK11 (Peutz-Jeghers): RR ~132 | Lifetime risk: 11–36% 🧬 PRSS1 (Hereditary Pancreatitis): RR 53–87 | Risk up to 55% by age 70 🧬 CDKN2A (FAMMM): RR 20–40 | Risk 17–25%

🚨 New Meta-Analysis in Metastatic non–Clear Cell RCC (nccRCC) Key pooled outcomes (23 studies): 🎯 ORR: 26.6% 🛡️ DCR: 57.8% ⏳ Median PFS: 6.6 months 📈 Median OS: 21.1 months Takeaway: ICI-based therapies, especially when combined with targeted agents, show superior efficacy

🔬 CRC Screening Face-Off: Stool 🧻 vs Blood 🩸 Not all non-invasive tests are created equal. Let’s break it down 👇 🧪 CRC Sensitivity ✅ Cologuard Plus: 95% ✅ ColoSense: 94% 🩸 Shield (blood): 80–83% ⚪ FIT: 67–91% ⚠️ Advanced Adenoma Detection (PREVENTION!) ✅ ColoSense:

Most viewed this week from JAMA Oncology: Nivolumab and ipilimumab were effective in treating advanced gynecological clear cell cancers, with a 54% response rate and 58% six-month progression-free survival. ja.ma/45Zg2mu

Check out our recent review article on ADCs in breast cancer! Grateful for the mentorship and guidance of Aditya Bardia, MD and Dr. John Glaspy throughout this work. hematologyandoncology.net/archives/july-…

In this OncLive.com video series, UCLA’s Marla Lipsyc-Sharf, MD discusses the role of ctDNA in breast cancer surveillance and what it could mean for patient care. Watch the episodes here: bit.ly/3TT071J

Best of ASCO 2025 review highlights: 1. Multiple Myeloma - CARTITUDE-1: 5-year survival showed 30% of patients are free of progression after CAR-T! Median OS: 5 years! These pts had lower disease burden going into CAR-T not lower risk disease ascopubs.org/doi/10.1200/JC…

2. Gyn cancers TRUST trial - ovarian cancer Upfront cytoreductive surgery vs neoadjuvant chemotherapy - some improvement on PFS (2-3mts) but no survival benefit to upfront surgery - higher rates of bowel resections and ostomies in upfront surgery- both options reasonable

More on GYN: ROSELLA trial- very exciting improved survival with relacorilant w nabpaclitaxel in difficult to treat platinum resistant high grade serous ovarian cancer

Implementation of DPYD & UGT1A1 testing in GI cancer 🔗 ascopubs.org/doi/10.1200/PO… 📊 288 pts; 225 FP/IRI 🧪 57% results pre-cycle 1 (TAT 10d) 💊 69% w/ DGI had dose cut pre-treatment 📉 Fewer severe TRAEs (38% vs 65%) & mods (38% vs 76%) vs biobank 🛡️ Feasible, improves safety

Liver Segments: Axial CT and 3D Reconstruction Source: xray_iq

#MedTwitter #OncTwitter #regulatory 📢 NEW #FDA Draft Guidance on Overall Survival in #Oncology #ClinicalTrials, covering trial design, #biostats considerations, posthoc & subgroup analyses, & more. Public comment period open now thru 10/20/2025. fda.gov/media/188274/d…

Exciting research news! Dr. Melissa Lechner and her team are exploring ways to prevent—or even reverse—rare endocrine side effects from cancer immunotherapy treatments using medicines already on the market. Read all about her impactful findings here: uclahs.fyi/4mfULu0

So proud of our Department of Medicine at UCLA Health rockstars, Drs. Marla Lipsyc-Sharf, MD , Jing Ji , Alexis LeVee, MD, & Yulia Zektser, MD, for their Conquer Cancer, the ASCO Foundation awards! With Aditya Bardia, MD support and leadership, young faculty at UCLA are driving progress .ASCO .UCLA Jonsson Comprehensive Cancer Center uclahealth.org/news/release/u…

📰 This recent study, now out in JNCI, on outcomes of subsequent treatment regimens after #TrastuzumabDeruxtecan in patients with #MetastaticBreastCancer found that: 👉Outcomes of post #TDXd treatments differ significantly by #MBC subtype and type of regimen administered

Thank you @Oncodaily! It’s truly an honor to represent JCO Global Oncology, ASCO, UCSF Helen Diller Family Comprehensive Cancer Ctr, and all of my patients💙 on this list of inspirational women in oncology!

Not as great a topical diclofenac but why not try both! These supportive care studies are so important for our patients! #bcsm